Fatigue in Patients with Advanced Cancer Not Improved by Oral Melatonin
the Cancer Therapy Advisor take:
No differences in physical fatigue, secondary outcomes, or explorative outcomes were observed between oral melatonin and placebo periods, according to an article published online in the journal Cancer.
This study included patients diagnosed with stage 4 cancer (age ≥18 years) who reported feeling significantly tired. Patients were recruited from the palliative care unit at a study institution and enrolled in the double-blind, randomized, placebo-controlled trial.
Participants in the study were administered a dose of 20 mg melatonin or an oral placebo each night for 1 week. After a washout period of 2 days occurred, the patients received the other dosage not administered in week one.
The Multidimensional Fatigue Inventory (MFI-20) primarily assessed physical fatigue, and primary analysis was conducted using complete complier analysis.
Overall, 72 patients were randomized, 50 completed the intervention, and 44 were complete compliers (meaning they consumed at least 5 capsules/week and answered the MFI-20 on days 1, 7, 10, and 17).
Results showed no significant differences in physical fatigue or other outcomes between the melatonin and placebo periods.
No differences in physical fatigue, secondary outcomes, or explorative outcomes observed between oral melatonin and placebo periods.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma
- CLL: Venetoclax Plus Rituximab Improves 2-Year PFS
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma